API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 134 articles Forum Github 13 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. VOR.NASDAQ

Vor Biopharma Inc (VOR NASDAQ) stock market data APIs

$0.8898 -0.2(-18.3%) as of September 9, 2024
Price chart is built with Anychart

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma Inc Financial Data Overview

1.09
0.8898
-
1.14
0.8277
0.7-3.14
74 555 K
68 399 K
0
-0.41
-0.34
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'VOR',
Type: 'Common Stock',
Name: 'Vor Biopharma Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00NBJRDT6',
ISIN: NULL,
CUSIP: NULL,
CIK: '1817229',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2021-02-05',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Vor Biopharma Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -121 204 000
  • Earnings Per Share -1.73
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Vor Biopharma Inc Earnings via APIs

  • Latest Release 2024-08-08
  • EPS/Forecast -0.42

Get Vor Biopharma Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Vor Biopharma Inc latest news via APIs

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

Vor Biopharma VOR, a clinical-stage company, announced dosing the first patient in its phase I/II study of VCAR33ALLO for the treatment of relapsed/refractory acute myeloid leukemia (AML). VCAR33ALL...

Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update

Vor Biopharma First patient dosed in company’s second clinical program with initial data expected in second half of 2024 Cash runway extended into second half of 2025 with clinical trials on track...
Do you have any questions?
support@eodhistoricaldata.com